marginal zone lymphoma: Disease Detail - Cancer Knowledgebase (CKB)

Profile Responses 1
Clinical Trials 181

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Therapy	Indication/Tumor Type	Response Type	Profile Response Detail
FGFR2 H167_N173del	Zoligratinib	marginal zone lymphoma	predicted - sensitive	detail...

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT00602693	Phase I	Sirolimus Allopurinol + Cyclophosphamide + Fludarabine	T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer	Completed	USA	0
NCT00671112	Phase I	Bortezomib + Everolimus	Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma	Terminated	USA	0
NCT01028716	Phase II	Filgrastim + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Fludarabine	Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Terminated	USA	0
NCT01732913	Phase III	Idelalisib Rituximab	Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas	Terminated	USA \| SWE \| ROU \| POL \| ITA \| ISR \| HUN \| GBR \| FRA \| ESP \| DEU \| CZE \| AUS	6
NCT01732926	Phase III	Idelalisib Bendamustine + Rituximab	Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas	Terminated	USA \| SWE \| POL \| ITA \| ISR \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| AUS	3
NCT01796171	Phase Ib/II	Lilotomab Betalutin Rituximab	A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-01)	Completed	USA \| TUR \| SWE \| POL \| NOR \| NLD \| ITA \| ISR \| IRL \| HUN \| HRV \| GBR \| FRA \| FIN \| ESP \| DNK \| CZE \| CHE \| CAN \| BEL \| AUT \| AUS	2
NCT01811368	Phase II	anti-thymocyte globulin + Ibritumomab tiuxetan + Rituximab Cyclosporine + Mycophenolate mofetil	Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma	Unknown status	USA	0
NCT01955499	Phase I	Ibrutinib + Lenalidomide	Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	Active, not recruiting	USA \| CAN	0
NCT01974440	Phase III	Ibrutinib Bendamustine + Rituximab Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Sulfate	A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma	Completed	USA \| TUR \| SWE \| POL \| ISR \| GBR \| FRA \| ESP \| DEU \| BRA \| BEL \| AUS \| ARG	6
NCT01976585	Phase Ib/II	CDX-301 + Poly ICLC	In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy	Completed	USA	0
NCT01994382	Phase I	Cerdulatinib	Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma	Completed	USA	0
NCT02000934	Phase I	Mivavotinib	A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies	Completed	USA \| ITA \| GBR \| ESP	0
NCT02049541	Phase I	Buparlisib + Rituximab	Study of BKM120; Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma	Completed	USA	0
NCT02106091	Phase I	AFM11	Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL	Terminated	USA \| POL \| DEU \| CZE	0
NCT02208037	Phase II		Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)	Completed	USA	0
NCT02254772	Phase Ib/II	Ipilimumab + Nelitolimod	TLR9 Agonist SD-101, Ipilimumab, and Radiation Therapy in Treating Patients With Low-Grade Recurrent B-cell Lymphoma	Completed	USA	0
NCT02266147	Phase Ib/II	Nelitolimod	Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma	Terminated	USA	0
NCT02339922	Phase II	Ixazomib + Rituximab	Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma	Active, not recruiting	USA	0
NCT02367040	Phase III	Rituximab Copanlisib	Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)	Completed	USA \| TUR \| SVK \| ROU \| POL \| NZL \| LTU \| ITA \| IRL \| HUN \| GRC \| FRA \| ESP \| DEU \| BRA \| BGR \| BEL \| AUT \| AUS \| ARG	17
NCT02369016	Phase III	Copanlisib	Phase III Copanlisib in Rituximab-refractory iNHL	Completed	TUR \| POL \| ITA \| GRC \| BRA \| BGR	4
NCT02381080	Phase I	Erythromycin + Ibrutinib + Voriconazole	Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy	Completed	ESP \| CAN	1
NCT02384954	Phase Ib/II	Nogapendekin alfa inbakicept + Rituximab	ALT-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma (iNHL) in Conjunction With Rituximab	Terminated	USA	0
NCT02457598	Phase I	Entospletinib + Tirabrutinib Tirabrutinib Idelalisib + Obinutuzumab + Tirabrutinib Entospletinib + Obinutuzumab + Tirabrutinib Idelalisib + Tirabrutinib	Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies	Terminated	USA \| GBR \| FRA	0
NCT02532257	Phase II	Ibrutinib + Lenalidomide + Rituximab	Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma	Completed	USA	0
NCT02564744	Phase II	Naratuximab emtansine + Rituximab	Study to Evaluate the Efficacy and Tolerability Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory DLBCL and Other Forms of NHL	Completed	USA \| POL \| ITA \| HUN \| CZE \| CHE \| BGR \| BEL	1
NCT02576275	Phase III	Bendamustine + Rituximab Duvelisib	A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)	Withdrawn	USA	0
NCT02626455	Phase III	Vincristine Sulfate Prednisone Aldoxorubicin + Cyclophosphamide + Prednisone + Rituximab + Vincristine Sulfate Copanlisib Bendamustine + Rituximab Rituximab	Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) (CHRONOS-4)	Terminated	USA \| TUR \| SVK \| ROU \| POL \| ITA \| ISR \| IRL \| HUN \| GRC \| GBR \| FRA \| FIN \| ESP \| DNK \| DEU \| CZE \| CAN \| BRA \| BGR \| BEL \| AUS	13
NCT02722668	Phase II	Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus anti-thymocyte globulin	UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep	Completed	USA	0
NCT02875223	Phase I	CC-90011	A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas	Terminated	ITA \| GBR \| FRA \| ESP	1
NCT02900716	Phase I	DTRMWXHS-12 + Everolimus + Pomalidomide DTRMWXHS-12 DTRMWXHS-12 + Everolimus	Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas	Completed	USA	0
NCT02914938	Phase I	zandelisib Rituximab + zandelisib	A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma	Terminated	USA \| CHE	0
NCT02950220	Phase I	Ibrutinib + Pembrolizumab	Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma	Completed	USA	0
NCT02953509	Phase Ib/II	Magrolimab + Rituximab	Trial of Hu5F9-G4 in Combination With Rituximab in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma	Terminated	USA \| GBR \| AUS	0
NCT03010358	Phase Ib/II	Entospletinib + Obinutuzumab	Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma	Completed	USA	0
NCT03015896	Phase Ib/II	Lenalidomide + Nivolumab	Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma	Active, not recruiting	USA	0
NCT03085173	Phase I	EGFRt/19-28z/4-1BBL CAR T cells	A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies	Active, not recruiting	USA	0
NCT03133221	Phase II	Idelalisib	1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation	Completed	USA	0
NCT03144674	Phase II	Parsaclisib	A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)	Completed	USA \| POL \| ITA \| ISR \| GBR \| FRA \| ESP \| DNK \| DEU \| BEL \| AUS \| ARG	0
NCT03147885	Phase Ib/II	Selinexor	Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma	Active, not recruiting	USA	0
NCT03198026	Phase II	Ibrutinib + Obinutuzumab	Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas	Active, not recruiting	USA	0
NCT03220347	Phase I	CC-90010	A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas	Terminated	ITA \| FRA \| ESP	1
NCT03277729	Phase Ib/II	CD20 CAR-T cells + Cyclophosphamide + Fludarabine	A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas	Active, not recruiting	USA	0
NCT03321643	Phase I	Atezolizumab + Gemcitabine + Oxaliplatin + Rituximab Atezolizumab + Rituximab	Atezolizumab, Gemcitabine, Oxaliplatin, and Rituximab in Treating Patients With Relapsed or Refractory Transformed Diffuse Large B-Cell Lymphoma	Active, not recruiting	USA	0
NCT03322865	Phase II	Obinutuzumab	Obinutuzumab in Marginal Zone Lymphoma	Active, not recruiting	DEU	0
NCT03364231	Phase II	Umbralisib	Study to Assess the Efficacy and Safety of Umbralisib in Patients With Non-Follicular Indolent Non-Hodgkin's Lymphoma	Completed	USA	0
NCT03422679	Phase Ib/II	CB-103	Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies	Terminated	USA \| FRA \| ESP \| DEU \| CHE	1
NCT03424122	Phase I	Ibrutinib + Parsaclisib Bendamustine + Parsaclisib + Rituximab Parsaclisib + Rituximab	INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)	Completed	USA \| ITA \| ESP	0
NCT03474744	Phase II	Copanlisib + Rituximab	Copanlisib and Rituximab in Marginal Zone Lymphoma Patients	Active, not recruiting	DEU \| AUT	0
NCT03479268	Phase I	Ibrutinib + MLN4924	Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma	Active, not recruiting	USA	0
NCT03498612	Phase II	Pembrolizumab	Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases	Terminated	USA	0
NCT03547115	Phase I	Voruciclib	A Phase 1 Study of Voruciclib in Subjects With B-Cell Malignancies	Unknown status	USA	0
NCT03571568	Phase Ib/II	Acalabrutinib + BI-1206 + Rituximab BI-1206 + Rituximab	A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL	Recruiting	USA \| SWE \| POL \| ESP \| DEU \| BRA	0
NCT03571828	Phase I	AMG562	Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma	Terminated	USA \| DEU \| CAN \| BEL	0
NCT03625037	Phase Ib/II	Epcoritamab-bysp	First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma (EPCORE™ NHL-1)	Active, not recruiting	USA \| SWE \| POL \| NLD \| ITA \| GBR \| FRA \| FIN \| ESP \| DNK \| DEU \| CAN \| AUS	2
NCT03682796	Phase I	TRPH-222	Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma	Completed	USA \| CAN	0
NCT03696784	Phase I	Rimiducid Bendamustine + Fludarabine + iC9-CAR.19-IL15-Transduced CB-NK	Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma	Active, not recruiting	USA	0
NCT03697512	Phase II	Ibrutinib + Rituximab	MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas (MALIBU)	Active, not recruiting	ITA \| FRA \| CHE \| BEL	1
NCT03711578	Phase II	Tenalisib	Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K delta/gamma Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)	Completed	USA \| AUS	0
NCT03740529	Phase Ib/II	Cyclophosphamide + Doxorubicin + Pirtobrutinib + Prednisone + Rituximab + Vincristine Sulfate Pirtobrutinib + Rituximab + Venetoclax Pirtobrutinib + Venetoclax Pirtobrutinib	A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL	Completed	USA \| SWE \| POL \| ITA \| GBR \| FRA \| CHE \| AUS	2
NCT03755154	Phase I	VOB560	Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia	Terminated	GBR \| FRA \| ESP \| AUS	0
NCT03779113	Phase Ib/II	HMPL-523	An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma	Terminated	USA \| POL \| ITA \| FRA \| FIN \| ESP \| DNK	0
NCT03786926	Phase Ib/II	HMPL-689	Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas	Terminated	USA \| POL \| ITA \| FRA \| FIN \| ESP	0
NCT03833180	Phase I	VLS-101	A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies	Completed	USA	0
NCT03846427	Phase II	Zanubrutinib	Study of Zanubrutinib (BGB-3111) in Patients With Marginal Zone Lymphoma	Completed	USA \| NZL \| ITA \| GBR \| FRA \| CZE \| AUS	2
NCT03884998	Phase I	Copanlisib + Nivolumab	Copanlisib and Nivolumab in Treating Participants With Richter's Transformation or Transformed Indolent Non-Hodgkin's Lymphoma	Active, not recruiting	USA	0
NCT03919175	Phase II	Rituximab + Umbralisib	Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma	Terminated	USA	0
NCT03920631	Phase I	Nivolumab	Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas (MicroBLITZ)	Withdrawn	USA	0
NCT04014205	Phase I	Orelabrutinib	A Study of Tyrosine Kinase Inhibitor ICP-022 in Patients With r/r B-Cell Malignancies	Unknown status	USA \| POL \| ISR	1
NCT04038359	Phase II	Duvelisib	A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects With Indolent Non-Hodgkin Lymphoma. (TEMPO)	Completed	USA \| POL \| ITA \| GBR \| DEU \| CZE	2
NCT04043845	Phase I	Ibrutinib + LY3214996	ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies	Withdrawn		0
NCT04072458	Phase I	BP1002	A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies	Active, not recruiting	USA	0
NCT04082936	Phase I	IGM-2323	A Safety and Pharmacokinetic Study of IGM-2323 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma	Terminated	USA \| ITA \| FRA \| ESP \| CZE \| AUS	1
NCT04136275	Phase I	Anti-CD37 CAR T cells	CAR-37 T Cells In Hematologic Malignancies	Completed	USA	0
NCT04205409	Phase II	Nivolumab	Nivolumab for the Treatment of Relapsed or Refractory Hematologic Malignancies	Active, not recruiting	USA	0
NCT04212013	Phase III	Ibrutinib Ibrutinib + Rituximab	A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma	Active, not recruiting	USA	0
NCT04223765	Phase I	Bendamustine + CAR.k.28 cells + Fludarabine CAR.k.28 cells + Cyclophosphamide + Fludarabine	Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma	Recruiting	USA	0
NCT04231747	Phase I	CC-97540	A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	Completed	USA \| CAN	0
NCT04245839	Phase II	Lisocabtagene maraleucel Cyclophosphamide + Fludarabine	A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) (TRANSCEND FL)	Active, not recruiting	USA \| SWE \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| AUT	1
NCT04268277	Phase II	Pembrolizumab + Rituximab	Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY	Terminated	DEU	0
NCT04277637	Phase I	BGB-11417 + Zanubrutinib BGB-11417	Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies	Active, not recruiting	USA \| NZL \| ITA \| GBR \| ESP \| DEU \| AUS	0
NCT04282018	Phase Ib/II	BGB-10188 + Zanubrutinib BGB-10188 + Tislelizumab BGB-10188	Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab	Completed	AUS	1
NCT04401020	Phase I	SAR442257	First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL	Active, not recruiting	USA \| NOR \| ESP \| CZE	1
NCT04416451	Phase II	Rituximab + Venetoclax	Study of Rituximab and Venetoclax in People With Newly Diagnosed Marginal Zone Lymphoma	Active, not recruiting	USA	0
NCT04431635	Phase I	Copanlisib + Nivolumab + Rituximab	Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma	Terminated	USA	0
NCT04447716	Phase I	Lenalidomide + Rituximab Hyaluronidase + Venetoclax Lenalidomide + Rituximab + Venetoclax	An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment	Active, not recruiting	USA	0
NCT04464798	Phase I	Iberdomide Iberdomide + Obinutuzumab Iberdomide + Rituximab	A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas	Terminated	USA \| ITA \| FRA \| DEU	2
NCT04491370	Phase Ib/II	Polatuzumab vedotin-piiq	Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma	Unknown status	USA	0
NCT04502706	Phase I	FSI-189 FSI-189 + Rituximab	Study of FSI-189 as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma	Terminated	USA	0
NCT04508647	Phase II	Ublituximab Ublituximab + Umbralisib	Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma	Completed	USA	0
NCT04540796	Phase I	JNJ-75348780	A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)	Completed	USA \| ISR \| GBR \| FRA \| ESP \| AUS	2
NCT04545762	Phase I	Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine	Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma	Recruiting	USA	0
NCT04578600	Phase I	Azacitidine + Lenalidomide + Obinutuzumab	CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma	Completed	USA	0
NCT04599634	Phase I	Magrolimab + Obinutuzumab + Venetoclax	Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies	Completed	USA	0
NCT04635683	Phase I	Lenalidomide + Ublituximab + Umbralisib	Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma	Withdrawn		0
NCT04646395	Phase II	Acalabrutinib + Tafasitamab-cxix	Study of Acalabrutinib and Tafasitamab in MZL Patients	Active, not recruiting	ITA \| CHE \| AUT	0
NCT04659044	Phase II	Polatuzumab vedotin-piiq + Rituximab + Rituximab Hyaluronidase + Venetoclax Rituximab Hyaluronidase + Venetoclax	Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	Terminated	USA	0
NCT04665115	Phase II	Ibrutinib	Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)	Withdrawn	USA	0
NCT04669171	Phase Ib/II	EO2463 EO2463 + Lenalidomide + Rituximab EO2463 + Rituximab	A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma (SIDNEY)	Recruiting	USA \| ITA \| FRA \| ESP	0
NCT04728893	Phase II	ARQ 531	Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)	Recruiting	USA \| TUR \| ROU \| POL \| ITA \| ISR \| IRL \| HUN \| GBR \| FRA \| ESP \| DNK \| DEU \| CZE \| CHE \| CAN \| BRA \| AUS \| ARG	3
NCT04745832	Phase III	Rituximab + zandelisib Bendamustine + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate	Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)	Terminated	USA \| TUR \| POL \| NZL \| NLD \| ITA \| HUN \| GRC \| GBR \| FRA \| ESP \| CAN \| BEL \| AUS	5
NCT04771572	Phase I	LP-118	Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.	Recruiting	USA	0
NCT04775745	Phase I	LP-168	Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.	Unknown status	USA	0
NCT04792502	Phase II	Lenalidomide + Mosunetuzumab-axgb	Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma	Recruiting	USA	0
NCT04799275	Phase II	Azacitidine + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate	Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma	Suspended	USA	0
NCT04809467	Phase Ib/II	Parsaclisib + Tafasitamab-cxix	A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) (topMIND)	Terminated	USA \| ITA \| FRA \| ESP \| DEU \| BEL \| AUT	0
NCT04830137	Phase I	NX-2127	A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies	Recruiting	USA	0
NCT04836832	Phase I	Acalabrutinib + Duvelisib	Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma	Withdrawn		0
NCT04842877	Phase II	DS-3201b	Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma	Active, not recruiting	FRA \| BEL	0
NCT04844866	Phase II	Bendamustine + Polatuzumab vedotin-piiq + Rituximab Gemcitabine + Oxaliplatin + Rituximab Zamtocabtagene autoleucel	Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients (DALY 2-EU)	Active, not recruiting	TUR \| POL \| NLD \| ITA \| HUN \| HRV \| FRA \| FIN \| ESP \| DEU \| CZE \| BEL \| AUT	1
NCT04861779	Phase I	HSK29116	A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies	Unknown status	AUS	1
NCT04883437	Phase II	Acalabrutinib + Obinutuzumab	Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas	Recruiting	USA	0
NCT04903197	Phase I	Lenalidomide + VAY736 VAY736	Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma	Terminated	ITA \| DEU \| AUS	4
NCT04970901	Phase I	Obinutuzumab Loncastuximab tesirine-lpyl + Mosunetuzumab-axgb Loncastuximab tesirine-lpyl + Polatuzumab vedotin-piiq Glofitamab-gxbm + Loncastuximab tesirine-lpyl	A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)	Recruiting	USA \| ITA \| GBR \| ESP \| CZE \| BEL	0
NCT05003141	Phase I	PSB202	PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies	Unknown status	USA \| AUS	1
NCT05006716	Phase I	BGB-16673	A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies (CaDAnCe-101)	Recruiting	USA \| TUR \| SWE \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| AUS	5
NCT05008055	Phase II	Capivasertib	Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL)	Completed	USA \| GBR \| FRA \| ESP \| DNK \| CAN	1
NCT05020015	Phase II	iC9-CAR.19-IL15-Transduced CB-NK Cyclophosphamide + Fludarabine	A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)	Active, not recruiting	USA	0
NCT05025800	Phase Ib/II	Evorpacept + Lenalidomide + Rituximab	ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma	Active, not recruiting	USA	0
NCT05100862	Phase III	Rituximab + Zanubrutinib Lenalidomide + Rituximab Obinutuzumab + Zanubrutinib	A Study of Zanubrutinib Versus Lenalidomide in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (MAHOGANY)	Recruiting	USA \| TUR \| ROU \| POL \| ITA \| ISR \| IRL \| GRC \| GBR \| FRA \| ESP \| DEU \| CZE \| CHE \| CAN \| BRA \| BGR \| BEL \| AUT \| AUS \| ARG	7
NCT05131022	Phase I	NX-5948	Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies	Recruiting	USA \| POL \| NLD \| ITA \| GBR \| FRA \| ESP \| CHE	0
NCT05169658	Phase II	Mosunetuzumab-axgb + Obinutuzumab + Polatuzumab vedotin-piiq	Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma	Completed	USA	0
NCT05205161	Phase Ib/II	AZD0466	A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma	Terminated	USA \| ITA \| FRA \| ESP \| AUS	2
NCT05207670	Phase II	Mosunetuzumab-axgb + Tocilizumab	A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun)	Active, not recruiting	USA	0
NCT05211336	Phase I	Lenalidomide + Nivolumab Ibrutinib + Lenalidomide + Obinutuzumab + Prednisone + Venetoclax	Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid With Nivolumab (VIPOR-Nivo) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System	Active, not recruiting	USA	0
NCT05256641	Phase Ib/II	Acalabrutinib	Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma	Recruiting	USA	0
NCT05275504	Phase I	TT-01488	Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies	Unknown status	USA	0
NCT05336409	Phase I	CNTY-101	A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies (ELiPSE-1)	Terminated	USA	0
NCT05338346	Phase I	ATG-018	A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies (ATRIUM)	Terminated	AUS	0
NCT05348889	Phase Ib/II	1A46	First-in-Human (FIH) Trial of 1A46 in Subjects With Advanced CD20 and/or CD19 Positive B-cell Hematologic Malignancies	Terminated	USA	0
NCT05360238	Phase Ib/II	MB-106	Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL	Terminated	USA	0
NCT05424822	Phase I	JNJ-80948543	A Study of JNJ-80948543, a T Cell Redirecting Antibody, in Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)	Active, not recruiting	USA \| POL \| ISR \| FRA \| DNK \| AUS	2
NCT05602363	Phase I	AS-1763	AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma	Recruiting	USA	0
NCT05607420	Phase Ib/II	Alemtuzumab UCART20X22	Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma (NatHaLi-01)	Recruiting	USA \| FRA \| ESP	0
NCT05702853	Phase Ib/II	CD19-CD34 CAR transduced T-cells Cyclophosphamide + Fludarabine	Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL	Recruiting	USA	0
NCT05737628	Phase I	BYON4228 + Rituximab	First-in-human Dose Escalation and Expansion Study With the SIRPalpha-directed Monoclonal Antibody BYON4228	Active, not recruiting	NLD \| ITA \| GBR \| ESP	0
NCT05753501	Phase I	ABBV-101	Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies	Recruiting	USA \| ITA \| ISR \| GBR \| FRA \| ESP \| DEU \| CAN	1
NCT05773040	Phase I	JV-213	A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas	Recruiting	USA	0
NCT05780034	Phase I	AC0676	A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies	Recruiting	USA	0
NCT05783596	Phase II	Glofitamab-gxbm + Obinutuzumab	Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma	Active, not recruiting	USA	0
NCT05784441	Phase I	JNJ-90009530	A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)	Active, not recruiting	USA \| ISR \| GBR \| AUS	0
NCT05828589	Phase I	BGB-21447	A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies	Active, not recruiting	USA \| NZL \| AUS	1
NCT05852717	Phase II	Cisplatin + Dexamethasone + Epcoritamab-bysp + Gemcitabine	Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma	Recruiting	USA	0
NCT05878184	Phase I	Cyclophosphamide + Fludarabine SC291	Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)	Active, not recruiting	USA \| AUS	0
NCT05879744	Phase I	CLN-978	A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)	Active, not recruiting	USA	0
NCT05950165	Phase Ib/II	CHO-H01 + Lenalidomide CHO-H01	A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma	Recruiting	USA	1
NCT05967416	Phase I	SIRPant-M	Phase 1, Open-Label Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma	Recruiting	USA	0
NCT05990465	Phase I	LV20.19 CAR-T cells + Pirtobrutinib	LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies	Recruiting	USA	0
NCT06006117	Phase III	Lenalidomide + Rituximab Lenalidomide + Mosunetuzumab-axgb Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Bendamustine + Rituximab	Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma	Recruiting	ITA \| FRA \| DEU \| BEL	1
NCT06014762	Phase I	P-CD19CD20-ALLO1	P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies	Recruiting	USA	0
NCT06026319	Phase I	CD79b-19 CAR T cells Cyclophosphamide + Fludarabine	CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma	Recruiting	USA	0
NCT06088654	Phase Ib/II	IPH6501	Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma	Recruiting	USA \| FRA \| AUS	0
NCT06149286	Phase III	Lenalidomide + Rituximab Lenalidomide + Odronextamab	A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Participants With Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5)	Recruiting	USA \| TUR \| POL \| ITA \| ISR \| GBR \| FRA \| ESP \| DEU \| CZE \| BRA \| BEL \| AUT \| AUS	4
NCT06191887	Phase I	Bendamustine BAFFR-CAR T cells Cyclophosphamide + Fludarabine	B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies	Recruiting	USA	0
NCT06248086	Phase I	ASP101G + ASP2802	A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas	Terminated	AUS	0
NCT06285422	Phase I	Cyclophosphamide + Fludarabine SC262	Study Evaluating SC262 in Subjects With r/r B-cell Malignancies (VIVID)	Active, not recruiting	USA	0
NCT06300528	Phase II	Pemigatinib	Pemigatinib for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma or Marginal Zone Lymphoma	Recruiting	USA	0
NCT06340737	Phase I	Anti-CD22 CAR T cells	AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas	Recruiting	USA	0
NCT06350318	Phase II	Rituximab + Zanubrutinib	Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas	Recruiting	USA	0
NCT06378190	Phase Ib/II	TranspoCART19	Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology (TranspoCART19)	Recruiting	ESP	0
NCT06390956	Phase II	Pirtobrutinib Pirtobrutinib + Rituximab	Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)	Recruiting	USA	0
NCT06392477	Phase I	DR-0201	A Study of DR-0201 in Subjects With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma	Recruiting	AUS	4
NCT06442475	Phase II	Mosunetuzumab-axgb	Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma	Recruiting	USA	0
NCT06484920	Phase II	Pembrolizumab + Tretinoin	A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL	Recruiting	USA	0
NCT06492304	Phase Ib/II	CTX131	A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies	Recruiting	USA \| AUS	0
NCT06510309	Phase II	Rituximab + Venetoclax	A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma	Not yet recruiting	USA	0
NCT06561425	Phase Ib/II	GLPG5101	A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma (Atalanta-1)	Active, not recruiting	USA \| NLD \| BEL	0
NCT06563505	Phase II	Mosunetuzumab-axgb + Zanubrutinib	A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma	Recruiting	USA	0
NCT06563596	Phase II	Epcoritamab-bysp + Rituximab + Zanubrutinib	Epco, Zanu, Ritux for R/R FL or MZL	Recruiting	USA	0
NCT06569680	Phase II	Mosunetuzumab-axgb	Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma	Recruiting	USA	0
NCT06590961	Phase I	UBX-303061	UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies	Recruiting	USA \| POL	1
NCT06708897	Phase I	Eiletoclax	A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas	Recruiting	USA	0
NCT06792825	Phase II	Lenalidomide + Rituximab + Tafasitamab-cxix	HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL	Recruiting	USA	0
NCT06796998	Phase II	Epcoritamab-bysp	Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)	Recruiting	USA	0
NCT06824701	Phase I	Obinutuzumab + Rituximab + Tazemetostat + Zanubrutinib	Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (TARZAN)	Recruiting	USA	0
NCT06859008	Phase I	BGB-11417 + Zanubrutinib	Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	Recruiting	USA	0
NCT06905509	Phase II	Cytarabine + Dexamethasone + Epcoritamab-bysp + Oxaliplatin + Rituximab Epcoritamab-bysp + Gemcitabine + Oxaliplatin Carboplatin + Cytarabine + Dexamethasone + Epcoritamab-bysp + Rituximab Carboplatin + Epcoritamab-bysp + Etoposide + Ifosfamide + Rituximab	Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma	Recruiting	USA	0
NCT06980116	Phase I	EXS73565	Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies	Recruiting	GBR \| ESP	0
NCT07108868	Phase I	MB-CART2219.1	A Phase I Dose Finding Study of MB-CART2219.1	Recruiting	DEU	0
NCT07166549	Phase I	Anti-CD19-CD20 CAR T cells	Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial) (BaseCAR-01)	Not yet recruiting	CHE	0
NCT07168486	Phase I	LTG2950 Cyclophosphamide + Fludarabine	CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas	Enrolling by invitation	USA	0
NCT07225439	Phase I	Aldesleukin + Rituximab + Tafasitamab-cxix Cyclophosphamide + Fludarabine	Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)	Not yet recruiting	USA	0

ID	DOID:0050748
Name	marginal zone lymphoma
Definition	A B-cell lymphoma arising from the marginal zone of lymphoid tissues that is characterized by the presence of small to medium sized atypical lymphocytes.
Source	DiseaseOntology.org
Alt Ids
Xrefs	ICDO:9699/3 MESH:D018442
Path	disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma B-cell lymphoma marginal zone lymphoma

marginal zone lymphoma
Disease Detail

Contact

Filtering

Sorting

marginal zone lymphomaDisease Detail

Contact

Filtering

Sorting

marginal zone lymphoma
Disease Detail